SYRE · Insider Trading
Spyre Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by SYRE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$1.38M |
| 2026-10-02 | Heidy King-Jones | See Remarks | MIXED | — | −$2.21M |
| 2026-10-02 | Scott L Burrows | Chief Financial Officer | MIXED | — | −$1.90M |
| 2026-09-03 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$1.31M |
| 2026-09-03 | Scott L Burrows | Chief Financial Officer | MIXED | −18,232 | −$2.18M |
| 2026-09-03 | Heidy King-Jones | See Remarks | MIXED | — | −$2.07M |
| 2026-08-10 | Jeffrey W. Albers | Director | MIXED | −18,000 | −$2.35M |
| 2026-08-05 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$1.43M |
| 2026-08-05 | Scott L Burrows | Chief Financial Officer | MIXED | — | −$608.02K |
| 2026-07-02 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$1.32M |
| 2026-07-02 | Sheldon Sloan | Chief Medical Officer | MIXED | — | −$502.04K |
| 2026-07-02 | Scott L Burrows | Chief Financial Officer | MIXED | — | −$549.29K |
| 2026-06-26 | Scott L Burrows | Chief Financial Officer | MIXED | — | −$1.09M |
| 2026-06-23 | Michael Thomas Henderson | Director | Sell | −20,000 | −$2.00M |
| 2026-06-23 | Fairmount Funds Management LLC | Director | MIXED | −16,072,404 | −$1.60B |
| 2026-06-03 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$1.06M |
| 2026-06-03 | Scott L Burrows | Chief Financial Officer | MIXED | — | −$424.19K |
| 2026-06-03 | Sheldon Sloan | Chief Medical Officer | MIXED | — | −$396.15K |
| 2026-05-29 | Michael Thomas Henderson | Director | A | +8,026 deriv. | — |
| 2026-05-29 | Tomas Kiselak | Director | A | +24,078 deriv. | — |
| 2026-05-29 | Laurie Stelzer | Director | A | +8,026 deriv. | — |
| 2026-05-29 | Mark C. McKenna | Director | A | +8,026 deriv. | — |
| 2026-05-29 | Jeffrey W. Albers | Director | A | +8,026 deriv. | — |
| 2026-05-29 | Sandra Milligan | Director | A | +8,026 deriv. | — |
| 2026-05-08 | Michael Thomas Henderson | Director | Sell | −80,000 | −$5.95M |
| 2026-05-01 | Scott L Burrows | Chief Financial Officer | MIXED | — | −$710.88K |
| 2026-05-01 | Sheldon Sloan | Chief Medical Officer | MIXED | — | −$3.45M |
| 2026-05-01 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$1.07M |
| 2026-04-03 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$739.91K |
| 2026-04-03 | Sheldon Sloan | Chief Medical Officer | MIXED | — | −$225.53K |
| 2026-04-03 | Scott L Burrows | Chief Financial Officer | MIXED | — | −$261.33K |
| 2026-03-03 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$632.87K |
| 2026-03-03 | Scott L Burrows | Chief Financial Officer | MIXED | — | −$65.37K |
| 2026-02-04 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$492.05K |
| 2026-01-23 | Michael Thomas Henderson | Director | J | +63,227 | — |
| 2026-01-13 | Sheldon Sloan | Chief Medical Officer | A | +140,000 deriv. | — |
| 2026-01-13 | Cameron Turtle | Chief Executive Officer | A | +528,000 deriv. | — |
| 2026-01-13 | Heidy King-Jones | See Remarks | A | +140,000 deriv. | — |
| 2026-01-13 | Scott L Burrows | Chief Financial Officer | A | +140,000 deriv. | — |
| 2026-01-06 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$460.13K |
| 2025-12-03 | Cameron Turtle | Chief Executive Officer | Sell | −15,000 | −$435.36K |
| 2025-11-05 | Cameron Turtle | Chief Executive Officer | Sell | −45,000 | −$1.05M |
| 2025-09-03 | Scott L Burrows | Chief Financial Officer | Sell | −18,428 | −$299.64K |
| 2025-06-02 | Laurie Stelzer | Director | A | +25,000 deriv. | — |
| 2025-06-02 | Mark C. McKenna | Director | A | +25,000 deriv. | — |
| 2025-06-02 | Jeffrey W. Albers | Director | A | +25,000 deriv. | — |
| 2025-06-02 | Sandra Milligan | Director | A | +25,000 deriv. | — |
| 2025-06-02 | Michael Thomas Henderson | Director | A | +25,000 deriv. | — |
| 2025-06-02 | Fairmount Healthcare Fund II L.P. | Director | A | +200,000 deriv. | — |
| 2025-01-17 | Scott L Burrows | Chief Financial Officer | A | +95,500 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Cameron Turtle | Chief Executive Officer | 551,940 | $51.28M |
| Fairmount Healthcare Fund II L.P. | Director | 406,038 | $37.72M |
| Tomas Kiselak | Director | 406,038 | $37.72M |
| Scott L Burrows | Chief Financial Officer | 79,991 | $7.43M |
| Michael Thomas Henderson | Director | 68,606 | $6.37M |
| Jeffrey W. Albers | Director | 24,360 | $2.26M |
| Heidy King-Jones | See Remarks | 7,545 | $701.01K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SYRE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.